newsfilter
← Latest News
Business Wire·

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

First presentation of initial LuMIERE Phase 1 data demonstrated a manageable safety profile with preliminary evidence of activity Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose No serious adverse events, treatment discont